Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
AstraZeneca PLC (LON:AZN) announced plans to transfer its U.S. trading venue from Nasdaq to the New York Stock Exchange (NYSE), a move designed to broaden access to global investors and enhance long-term growth opportunities. The Anglo-Swedish pharmaceutical giant emphasized that it will remain headquartered and tax resident in the United Kingdom, while continuing to maintain listings in London and Stockholm.
Following the announcement, AstraZeneca shares gained 1.5% in early London trading, reflecting investor optimism about the transition. Chair Michel Demare noted the strategic importance of the shift, explaining that a harmonized global listing structure will help support sustainable growth and provide exposure to a more diverse mix of institutional and retail investors, particularly within the U.S. market.
The decision comes amid mounting pressure on the U.K. equity market as major corporations seek higher valuations abroad. Several well-known firms, including Unilever with its ice cream business spin-off and commodities group Glencore, have explored alternatives to London. AstraZeneca’s move underscores this broader trend of companies reassessing the appeal of the London Stock Exchange.
Despite speculation earlier this year that AstraZeneca might abandon its London presence entirely, the company confirmed it remains committed to its U.K. base. However, the drugmaker has scaled back certain domestic investments, including shelving a planned £200 million expansion of its Cambridge research facility, citing challenging business conditions in the country.
Political and regulatory pressures are also influencing AstraZeneca’s global strategy. With the U.S. government taking a tougher stance on the pharmaceutical industry, including calls for greater domestic investment, AstraZeneca aims to balance market access with operational flexibility. The proposal still requires shareholder approval, with a vote scheduled for November 3.
By securing a NYSE listing while retaining its European bases, AstraZeneca is positioning itself to attract a wider pool of global investors, strengthen its market presence, and support its long-term strategy for sustainable growth.
